Life Sciences

  • July 17, 2026

    Taxation With Representation: Freshfields, Slaughter And May

    In this week's Taxation With Representation, Uber Technologies Inc. buys food delivery company Delivery Hero SE, engineering group ABB Ltd. acquires flow technology company Rotork PLC, and Eli Lilly and Co. buys drug developer AtaiBeckley Inc.

  • July 17, 2026

    The Biggest Trade Secret Rulings Of 2026: A Midyear Report

    The Federal Circuit issued two of the year's most consequential trade secret rulings within days of each other, wiping out Insulet's victory in a wearable insulin patch pump case while reopening a software company's path to potentially larger damages in a dispute with Ford Motor Co. Here, Law360 highlights the biggest trade secret decisions so far this year.

  • July 17, 2026

    UK Litigation Roundup: Here's What You Missed In London

    The past week in London has seen Snapchat and Dolby press on with a fresh infringement claim in their ongoing patent battle, The Telegraph face an intellectual property claim by a photo archive, a group of international human rights barristers and chambers sued, and oil business Equinor embroiled in a contract dispute with BP after recently acquiring full ownership in their offshore project. Here, Law360 looks at these and other new claims in the U.K.

  • July 17, 2026

    Commerce Opens Duty Probes Into Chinese Supplements

    The U.S. Department of Commerce is investigating whether certain dietary supplements imported from China are being sold at unfair prices and should be subject to antidumping and countervailing duties, it said Friday.

  • July 16, 2026

    FDA, Drugmakers Urge 5th Circ. To Allow Abortion Pill By Mail

    The U.S. Food and Drug Administration and the makers of the abortion medication mifepristone have urged the Fifth Circuit not to reinstate an in-person dispensing requirement, arguing that doing so would disrupt the government's ongoing review of the drug, "threaten chaos" and defy the U.S. Supreme Court.

  • July 16, 2026

    Pharma Co. Beats Investor Suit Over Prostate Drug Trial

    A Wisconsin federal judge ruled Wednesday that investors of prostate cancer treatment developer Essa Pharma Inc. have not shown they were misled by the company on the efficacy of its lead drug candidate, which was not as effective as an existing treatment for certain cancer patients in a terminated clinical trial.

  • July 16, 2026

    Fed. Circ. Asked Not To Shift Moderna Vax Patent Case To Gov't

    Drugmakers like Novartis, former federal judges, a startup group and others have urged the Federal Circuit to reject calls to shift liability in a COVID-19 vaccine patent suit against Moderna to the federal government, saying that doing so would undermine patent rights.

  • July 16, 2026

    DEA Judge Lays Out Next Steps Following End Of Pot Hearing

    A U.S. Drug Enforcement Administration administrative law judge has laid out upcoming deadlines following the conclusion of hearings on a proposal to move marijuana to Schedule III under the Controlled Substances Act.

  • July 16, 2026

    Senate Democrats Revive Bill To End Federal Marijuana Ban

    Senate Democrats on Thursday once again reintroduced a cannabis legalization bill that would remove the drug entirely from the ambit of the Controlled Substances Act and impose a tax-and-regulate scheme akin to what is currently in place for alcohol and tobacco.

  • July 16, 2026

    Walgreens Sues Mass. Medicaid Program Over Drug Rates

    Walgreens says administrators of the Massachusetts Medicaid program cannot rely on drug prices negotiated with pharmacy benefit managers to determine reimbursement rates, in a challenge to the state's effort to claw back $242,000 in alleged overpayments.

  • July 16, 2026

    Fed. Circ. Vacates $12.7M Copyright Award Against Gov't

    The Federal Circuit on Thursday vacated a $12.7 million copyright award against the federal government over unauthorized copies of software for a project on military health records, holding that the trial judge improperly relied on the project's later cancellation and awarded enhanced damages for willful infringement against the government.

  • July 16, 2026

    Ropes & Gray, Latham Steer $3.8B Eli Lilly Mental Health Deal

    Eli Lilly said Thursday it will acquire New York-based drug developer AtaiBeckley Inc. in a deal valued at up to $3.8 billion, expanding its pipeline of experimental treatments for depression and other mental health disorders.

  • July 16, 2026

    USTR Broadens Exemptions Ahead Of 25% Brazil Tariff

    A 25% tariff on Brazilian goods will begin next week with an expanded exemption list following public comments on the action, U.S. Trade Representative Jamieson Greer announced.

  • July 16, 2026

    Diagnostics Co. Labcorp Settles FCA Claims For $14.5M

    Diagnostics testing company Labcorp will pay $14.5 million to settle False Claims Act allegations that it submitted unnecessary Medicare claims for urine drug tests, the Massachusetts U.S. attorney's office announced.

  • July 15, 2026

    Albertsons Slow To Review Wash. Opioid Sales, Judge Told

    Albertsons conducted few reviews of opioid dispensing by its Washington pharmacies for years after establishing a controlled substances compliance team, according to testimony played on Day 3 of a bench trial in the state's lawsuit accusing the company and its Safeway subsidiary of exacerbating Washington's opioid epidemic.

  • July 15, 2026

    Circuit-By-Circuit Guide To The US Supreme Court's Term

    Federal appeals courts had wide-ranging successes and struggles during the U.S. Supreme Court's recently completed term: One had its best showing in years following its worst showing in years; one felt déjà vu after recently starting to find favor with the justices; and one saw its reputation for independence occupy a rare role in the Supreme Court spotlight.

  • July 15, 2026

    Unilever Tangled In Litigation Again Over TRESemme

    Unilever's personal care unit was hit with a products liability lawsuit in New Jersey federal court Tuesday by customers who say the company's TRESemme shampoo products caused them to suffer scalp irritation, bald spots or their hair to fall out in clumps.

  • July 15, 2026

    Acorda Can't Add $66M To Award In Ampyra Royalty Fight

    The Second Circuit on Wednesday refused to alter an arbitral award issued to Acorda Therapeutics to include nearly $66 million beyond the $16.6 million it won in a multiple sclerosis drug dispute, saying the company "slept on its rights" and couldn't change the result now.

  • July 15, 2026

    Bristol Myers Sues Generics Cos. Over Planned Cardiac Drug

    Bristol Myers Squibb and MyoKardia have filed patent infringement suits in Delaware against a variety of pharmaceutical companies, including MSN Laboratories and Dr. Reddy's Laboratories, targeting their planned generic versions of the cardiac drug Camzyos.

  • July 15, 2026

    Braveheart Bio, Attovia Join Growing Pipeline Of Biotech IPOs

    Two venture-backed biotechnology firms filed plans for initial public offerings this week, both with plans to raise around $100 million for their public debut.

  • July 15, 2026

    Polsinelli, Doctor Seek Toss Of 'Bad Faith' Patent Claims

    Polsinelli PC and a doctor who has been a client of the law firm have asked Mississippi and Tennessee federal courts to throw out Zavation Medical Products LLC and Choice Spine LLC's allegations that the firm and its client violated respective state laws by bringing "bad faith" patent infringement claims, saying the statutes the medical device makers rely on can't be brought by distributors or manufacturers.

  • July 15, 2026

    What To Watch In Massachusetts In The 2nd Half Of 2026

    As midsummer approaches, Massachusetts attorneys are focused on much more than just the Red Sox winning streak and the fallout from the Jaylen Brown trade; from a headline-grabbing federal prosecution to the midterm elections to cases that could shape the state's noncompete laws, practitioners have plenty on their radar in the latter half of the year.

  • July 15, 2026

    Squires Grants 10 PTAB Petitions, Denies 14 In Newest Order

    U.S. Patent and Trademark Office Director John Squires turned away 14 Patent Trial and Appeal Board petitions on Tuesday, while instituting another 10.

  • July 15, 2026

    9th Circ. Won't Revive Flea, Tick Meds Suit Against Bayer

    A Ninth Circuit panel gave short shrift to Tevra Brand LLC's bid to revive an antitrust suit alleging Bayer HealthCare LLC used exclusive contracts to lock up the market for a flea and tick treatment for dogs and cats, preserving Bayer's jury win.

  • July 15, 2026

    Covidien Hid Mesh Risk From Doctors, Bellwether Jury Told

    A Massachusetts federal jury in the first bellwether trial over Covidien LP's hernia mesh products was told Wednesday that doctors were not warned about how quickly a safety feature could dissolve after the mesh is implanted in a patient's body.

Expert Analysis

  • How Nasdaq's 23/5 Rule Will Alter Public Offering Strategies

    Author Photo

    The U.S. Securities and Exchange Commission's recent approval of Nasdaq's proposal to extend trading hours to 23 hours a day, five days a week, may reshape how certain public offerings are executed, particularly for confidentially marketed public offerings, say attorneys at Faegre Drinker.

  • The Paradoxical Duty To Adopt AI When You Can't Bill For It

    Author Photo

    Both billing for hours saved using artificial intelligence and preserving billable time by not adopting AI may violate rules of professional conduct, but until bar associations' ethics rules catch up to this emerging economic dilemma, firms must decide how to adjust fee structures themselves, says Ines Lassalle at Peyrot & Associates.

  • Tips For Litigating Life Sciences Investigations At The ITC

    Author Photo

    The International Trade Commission may soon become a significant battleground for life sciences companies as global intellectual property and trade disputes continue, increasing the importance of learning the ITC's unique considerations and litigation strategies, say attorneys at Crowell & Moring.

  • Ch. 15 Ruling Is A Restructuring Blueprint For Cannabis Cos.

    Author Photo

    The recent Cannabist Chapter 15 recognition order is arguably the most significant cannabis bankruptcy development in U.S. history, providing a concrete and tested road map by which such companies with foreign parent structures can access the protective machinery of U.S. bankruptcy law, say attorneys at Saul Ewing.

  • Unsecured Synthetic Royalties May Be Returning

    Author Photo

    Recent royalty monetization deals mark a notable shift in a market that had largely moved away from unsecured synthetic royalty structures after a multiyear freeze triggered by the Mallinckrodt bankruptcy decision in 2022, which exposed a legal risk inherent to the structure, says Peter Schwartz at Covington.

  • Series

    Cow Horse Makes Me A Better Lawyer

    Author Photo

    Moving an unwilling 800-pound cow while riding a horse at high speed is exhilarating, a little unhinged and, at least for me, a surprisingly effective training ground for litigation — both demand focus, preparation over rigid planning and the willingness to act despite fear, says Ashley Zitrin at Glenn Agre.

  • Protecting AI-Driven Innovation In Life Sciences IP

    Author Photo

    Recent developments, including the U.S. Patent and Trademark Office's evolving inventorship standards, and the impact of artificial intelligence on the "person of ordinary skill in the art" standard demand that life sciences companies elevate AI patent strategy to a top priority, says Sandra Haberny at Quinn Emanuel.

  • What Prop 65 Listings For Welding Fumes, Drugs Mean For Cos.

    Author Photo

    With California poised to add welding chemicals and three medications to its list of known carcinogens under Proposition 65, businesses must assess risks from nontraditional pharmaceutical dispensing, occupational and environmental exposures to welding operations, and downstream exposures from the manufacture of both types of substances, says Gregory Berlin at Alston & Bird.

  • High Court's Hikma Decision Reshapes 'Skinny Label' Suits

    Author Photo

    The U.S. Supreme Court's decision in Hikma v. Amarin marks a significant victory for generic drug manufacturers, but rather than putting an end to so-called skinny label inducement claims, it narrows and refocuses them, say attorneys at Sterne Kessler.

  • Virginia's Cannabis Retail Veto Leaves Industry In Legal Limbo

    Author Photo

    Virginia Gov. Abigail Spanberger's recent veto of legislation that would have established a regulated retail cannabis framework halts momentum built by the General Assembly, but it also sends important signals about what a future regulatory framework must address to survive, says Charles Slemp at Cozen.

  • Checking For AI Errors Is Now A Two-Way Street

    Author Photo

    A handful of recent federal and state cases demonstrate the importance of checking for errors generated by artificial intelligence not only in your own court submissions, but also your opponent's, as well as when catching opposing counsel's AI mistakes could result in an award for attorney fees, says Tamara Barago at Hollingsworth.

  • Series

    The Biz Court Digest: Shoring Up Corporate Law In Maryland

    Author Photo

    Launched more than 20 years ago to improve complex corporate adjudication, Maryland's Business and Technology Case Management Program has been a solid success in some areas, but there always is room for improvement, says Bill Krulak at Miles & Stockbridge.

  • State Enviro Agencies Give Cosmetics Regulation A Makeover

    Author Photo

    As state oversight of cosmetics rapidly expands, the new statutes and regulations governing these products are being implemented by environmental agencies rather than consumer product regulators, requiring manufacturers, distributors and retailers to reevaluate their supply chains and procedures, say attorneys at Baker Botts.

  • FDA's Chemical Review Process Heats Up Food Industry Risk

    Author Photo

    The U.S. Food and Drug Administration's newly announced process for postmarket assessment of food additives signals a significant shift away from historically limited oversight, introducing both strategic opportunities and material risks for food manufacturers, ingredient suppliers and others in the food supply chain, say attorneys at Morgan Lewis.

  • Series

    Competing At Poker Makes Me A Better Lawyer

    Author Photo

    Playing poker in male-dominated rooms taught me to treat skepticism as background noise when my opponents seem to underestimate me, to apply pressure when it matters and to adapt without losing strategic discipline — skills that are all indispensable in restructuring and insolvency matters, says Alexis Gambale at Pashman Stein.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.